eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2022
vol. 8
 
Share:
Share:
Original paper

Association between hypothyroidism and liver fibrosis risk: a systematic review and meta-analysis

Adinda Ayu Dyah Rahadini
1
,
Adinda Rahadina
1

1.
Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Clin Exp HEPATOL 2022; 8, 3: 188-194
Online publish date: 2022/09/26
Article file
- Association.pdf  [0.12 MB]
Get citation
 
PlumX metrics:
 

Introduction

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, and by 2030, it is predicted to be the primary cause of liver transplantation. Its rising prevalence is associated with increased metabolic syndrome, obesity, and insulin resistance [1, 2]. NAFLD presents a vast clinical spectrum from simple steatosis without liver fibrosis to cirrhosis caused by non-alcoholic steatohepatitis (NASH) [3]. NAFLD patients have a higher risk of adverse events compared to the general population. However, mortality risk is not the same across the spectrum, with NASH-related cirrhosis posing the greatest risk of mortality [4-6]. Early identification of a cohort with liver fibrosis is of paramount importance so that early counseling and treatment, as well as a referral to a transplantation center, can be performed. Because of the critical nature of early identification, an ongoing effort to identify other risk factors that may take part in the development of fibrosis is essential.

Thyroid hormone is essential for lipid and glucose metabolism, as well as mitochondrial function in the liver [7]. Hypothyroidism, both overt and subclinical, has been demonstrated to be an independent risk factor for the development of NAFLD [8]. However, its association with liver fibrosis, the more significant clinical entity, is less clear. We aimed to summarize the association between hypothyroidism and liver fibrosis risk.

Material and methods

Study selection

Our meta-analysis adhered to PRISMA guidelines. Two independent investigators conducted a literature search of PubMed and ProQuest from inception to June 30, 2021, restricting the search to studies involving humans and articles published in English. We used medical subject headings and free-text terms for the keywords, as shown in Table 1.

Table 1

Search strategy

SearchQueryResults
PubMed
#1((“Hypothyroidism”[Mesh]) OR (“Thyrotropin”[Mesh])) OR (((“hypothyroid”[All Fields]) OR (“thyroid stimulating hormone”[All Fields])) OR (“tsh”[All Fields]))77,497
#2((“Non-alcoholic Fatty Liver Disease”[Mesh]) OR ((“nonalcoholic fatty liver disease”[All Fields]) OR (“nafld”[All Fields]))) OR (“liver fibrosis”[All Fields])40,999
#3#1 AND #2111
ProQuest
S1(SU.exact(“LIVER DISEASES”) AND SU.exact(“FATTY LIVER”))3,517
S2Hypothyroidism OR hypothyroid OR thyrotropin46,778
S31 AND 2105

Eligibility criteria

We included studies if they met the following criteria: 1) the study was a cohort, case-control, or cross-sectional study, 2) the study estimated the association between the presence of hypothyroidism and risk of liver fibrosis or NASH, 3) the study reported odds ratios (ORs) with their respective 95% confidence intervals (CIs) or presented raw data. When the study carried out analyses with adjustment for confounding factors, we chose the adjusted over unadjusted OR. The excluded papers were: 1) studies with causes of liver fibrosis other than NAFLD spectrum, 2) short communication, correspondence, letters to the editor, conference abstracts, review, or case reports, 3) desirable data could not be retrieved, 4) full-text articles were not available, 5) non-English articles.

Assessment of bias risk

The risk of bias of included studies was separately assessed by two investigators using the Newcastle-Ottawa Scale (NOS). Studies with an NOS score < 7 were considered to have a high risk of bias, whereas those with a score ≥ 7 were considered to have a low risk of bias.

Data extraction

The same two investigators independently extracted the following data from each study using a prespecified form: author, year, study design, country, sample size, hypothyroidism definition, NAFLD diagnosis criteria, NASH, significant liver fibrosis, advanced liver fibrosis diagnosis criteria, and adjustment used. We contacted authors for additional data or clarification when needed.

Statistical analysis

We estimated the impact of hypothyroidism on the risk of liver fibrosis and NASH through pooled OR with their corresponding 95% CI. Data were pooled based on fixed-effects or random-effects assumptions. P-values < 0.05 were considered to be significant. Higgins’ I2 statistic was used to assess heterogeneity. If the value of I2 was < 50%, the fixed-effect models could be applied. Otherwise, random effects could be used. We planned to assess publication bias through a funnel plot if included studies reached the minimum number of 10. An asymmetric plot could suggest publication bias. All statistical analyses were performed using Review Manager version 5.4 (The Cochrane Collaboration).

Results

After deleting duplicates and reviewing titles and abstracts for eligibility, 203 of the 216 potential records identified by the search approach were excluded. Eight studies were found to be eligible for qualitative and quantitative synthesis after additional full-text inspections for 13 articles (Fig. 1).

Fig. 1

PRISMA Flow diagram

/f/fulltexts/CEH/47596/CEH-8-47596-g001_min.jpg

Study characteristics

The baseline characteristics of the eight studies are summarized in Table 2. The studies involved 14,588 patients, ranging from 103 to 9,419 patients in each study, originating from 7 different countries. Studies were published between 2003 and 2021. Four studies reported the association between overt hypothyroidism and NASH risk. Four studies investigated the impact of subclinical hypothyroidism, defined as an increased level of serum thyroid stimulating hormone (TSH) with normal FT4, and two studies, by Kim et al. [9] and Martínez-Escudé et al. [10], used a TSH cut-off of ≥ 2.5, also known as low-normal thyroid function. Low-normal thyroid function was said to be more robust than subclinical hypothyroidism in detecting cardio-metabolic consequences [11, 12]. The diagnosis criteria of NASH, significant liver fibrosis, and advanced liver fibrosis varied across studies, as shown in Table 2.

Table 2

Study characteristics

Author, year, study design, country, sample sizeHypothyroidism definitionNAFLD diagnosis criteriaOutcomeAdjustment used
Liangpunsakul, 2003, case-control, United States, 616Hypothyroidism was defined as prior prescription of synthetic T4NSNASH case was defined as patient attending Hepatology Clinic in Indiana University Hospital with well-documented NASH found in patient databaseNA
Mazo, 2011, cross-sectional, Brazil, 103Hypothyroidism was defined as prior prescription of synthetic T4NAFLD was diagnosed through liver biopsyNASH was diagnosed according to NASH activity scoreNA
Pagadala, 2012, case-control, United States, 633Hypothyroidism was defined as presenting a clinical diagnosis of hypothyroidism or prior prescription of synthetic T4NAFLD was diagnosed through liver biopsyNASH was diagnosed according to the NASH Clinical Research Network validated histological scoring systemAge, gender, ethnicity, BMI
Parikh, 2015, case-control, India, 800Hypothyroidism was defined as prior prescription of synthetic T4NAFLD was diagnosed through liver biopsyNASH was diagnosed and staged according to Brunt criteriaAge, gender, BMI
Bano, 2016, cohort, Netherlands, 9,419
Subclinical hypothyroidism was defined as serum TSH > 4.0 mIU/l and FT4 levels within the reference range
NAFLD was defined as the presence of fatty liver diagnosed using abdominal US in the absence of secondary causes. When US was not available, FLI measurement was used insteadSignificant liver fibrosis was defined as LS ≥ 8 kPa, examined using transient elastography
Advanced liver fibrosis: NA
Age, sex, cohort, alcohol intake, smoking, follow-up time, use of hypolipidemic drugs, total cholesterol, TG, BMI, HTN, diabetes
Kim, 2017, cross-sectional, South Korea, 425
Subclinical hypothyroidism was defined as serum TSH above 4.5 mIU/l within a normal thyroid hormone level
Low-normal thyroid function, defined as TSH ≥ 2.5
Ultrasonography-diagnosed fatty liver, shown as increased liver/kidney echogenicity and posterior attenuation
Exclusion criteria: significant alcohol consumption, viral hepatitis, and pre-existing chronic liver disease
NASH and liver fibrosis were examined through liver biopsy, assessed according to Brunt and Kleiner criteria
Significant liver fibrosis was defined as F2-F4, advanced fibrosis as F3-F4
No adjustment used for significant liver fibrosis
Advanced liver fibrosis analysis was adjusted for age, gender, BMI, diabetes, TG, and HOMA-IR
Tahara, 2019, cross-sectional, Japan, 140Subclinical hypothyroidism was defined as a serum TSH level of > 4 with an FT4 level between 0.90 and 1.80 ng/dlFatty liver was observed via ultrasonography when there was increased liver echogenicity (“bright liver”) and a contrast between hepatic and renal parenchymal tissues.Significant liver fibrosis: NA
Advanced liver fibrosis was defined as FIB-4 index ≥ 2.67
No adjustments used
Martinez-Escude, 2021, cross-sectional, Spain, 2,452TSH ≥ 2.5NAFLD was diagnosed if the FLI serological marker, which consists of TG, BMI, GGT, and WC, is ≥ 60Significant liver fibrosis was defined as LS ≥ 8 kPa, examined using transient elastography
Advanced liver fibrosis: NA
Age, sex, alcohol consumption, WC, TG, HDL, BP, glucose

[i] BMI – body mass index, BP – blood pressure, FIB-4 – Fibrosis-4 index, FLI – fatty liver index, FT4 – free T4 hormone, GGT – γ-glutamyl transferase, HDL – high density lipoprotein, HOMA-IR – homeostatic model assessment for insulin, HTN – hypertension, IU – international unit, kPa – kilopascal, LS – liver stiffness, NAFLD – non-alcoholic fatty liver disease, NA – not applicable, TG – triglyceride, TSH – thyroid stimulating hormone, US – ultrasonography, WC – waist circumference

Quality of included studies

The study quality ranged from 6 to 8, as shown in Table 3. Four studies were found to have a high risk of bias, whereas four were found to have a low risk of bias.

Table 3

Quality of included studies

StudySelectionComparabilityOutcome/ExposureNOS Score
Liangpunsakul, 20033216
Mazo, 2011336
Pagadala, 20121236
Parikh, 20153238
Bano, 20163238
Kim, 20172136
Tahara, 20193238
Martinez-Escude, 20213238

[i] NOS – Newcastle-Ottawa scale

Publication bias

We were not able to conduct publication bias assessment through the funnel plot as the included studies in the subgroup analysis did not reach 10 studies.

Subclinical hypothyroidism and significant liver fibrosis

Studies investigating the association between subclinical hypothyroidism and significant liver fibrosis are limited. Pooled results on the presence of subclinical hypothyroidism and the risk of liver fibrosis are shown in Figure 2. Presence of subclinical hypothyroidism was not significantly associated with significant liver fibrosis (pooled OR = 1.42, 95% CI = 0.81-2.50, p = 0.22).

Fig. 2

Forest plot of the association between subclinical hypothyroidism and risk of significant liver fibrosis

/f/fulltexts/CEH/47596/CEH-8-47596-g002_min.jpg

Subclinical hypothyroidism and advanced liver fibrosis

Subclinical hypothyroidism was significantly associated with advanced liver fibrosis, with pooled OR of 2.77, 95% CI = 1.65-4.65, p < 0.00. No heterogeneity was present, as shown in Figure 3 (I2 = 0%, p = 0.48).

Fig. 3

Forest plot of the association between subclinical hypothyroidism and risk of advanced liver fibrosis

/f/fulltexts/CEH/47596/CEH-8-47596-g003_min.jpg

TSH ≥ 2.5 and significant liver fibrosis

Two studies investigated the association between a TSH cut-off of ≥ 2.5 and significant liver fibrosis in NAFLD patients. A significant association was found between TSH ≥ 2.5 and significant liver fibrosis, shown in Figure 4, with no heterogeneity (OR = 1.61, 95% CI = 1.21-2.15, I2 = 0%).

Fig. 4

Forest plot of the association between thyroid stimulating hormone (TSH) ≥ 2.5 and risk of significant liver fibrosis

/f/fulltexts/CEH/47596/CEH-8-47596-g004_min.jpg

Hypothyroidism and NASH

Four studies assessed the relationship between overt hypothyroidism and NASH risk. Overt hypothyroidism was significantly associated with NASH risk with no heterogeneity, as shown in Figure 5 (OR = 2.38, 95% CI = 1.61-3.53, I2 = 44%).

Fig. 5

Forest plot of the association between hypothyroidism and risk of non-alcoholic steatohepatitis (NASH)

/f/fulltexts/CEH/47596/CEH-8-47596-g005_min.jpg

Discussion

Interpretation

The current research summarized the association between hypothyroidism and liver fibrosis risk from 8 observational studies. From our pooled results, subclinical hypothyroidism was significantly correlated with the development of advanced liver fibrosis in NAFLD patients. There was also a significant association between TSH cut-off of 2.5 and significant liver fibrosis. A significant association between overt hypothyroidism and NASH risk was also reported. However, no significant relationship was found between subclinical hypothyroidism and significant liver fibrosis.

The underlying mechanism has not been fully elucidated. Prior studies have demonstrated various mechanisms underlying the association between hypothyroidism, both subclinical and overt, with NAFLD. Thyroid hormone regulates major metabolic processes, one of which is intrahepatic lipolysis, mediated by lipophagy. Thyroid hormone also promotes lipid droplet entrapment, destruction of the lipid, and accelerated fatty acid oxidation, which will result in reduced steatosis in the liver [13]. In hypothyroid state, a decline of hepatic lipase activity triggered by reduced triglyceride clearance and hepatic triglyceride deposition can induce NAFLD. De novo lipogenesis, as well as a movement of free fatty acids to the liver, can also occur due to insulin resistance associated with hypothyroidism [14-16]. Reports from animal studies have stated that the use of an agonist agent targeting the thyroid receptor in the liver has been shown to reduce liver steatosis [17, 18]. Evidence regarding its use in humans, although limited, has been documented. Levothyroxine supplementation was proven to show benefit in a randomized clinical trial of 363 subclinical hypothyroid patients with dyslipidemia by significantly reducing the steatosis in the liver [19].

However, its association with liver fibrosis, the more important clinical entity, is less clear. Pathophysiologically speaking, the underlying mechanism may be due to the accumulation of extracellular matrix [20]. Prior research revealed that thyroid hormone might play a regulatory role in the activation of stellate cells in the liver, thus also suggesting its involvement in liver fibrosis signaling [21-24]. Experimental studies on myocardium have also indicated that hypothyroidism can induce upregulation of collagen type 1 gene expression, causing subsequent fibrosis [25-27]. Administration of thyroid hormone promotes metalloproteinase activity, leading to more collagen degradation [28]. This suggests a potential effect of thyroid hormone as NAFLD and fibrosis treatment. Some studies have started to report drugs under development targeting thyroid hormone receptors in the liver as potential nonalcoholic steatohepatitis (NASH) treatment [29, 30]. Another mechanism may also be explained by hepatocellular damage induced by thyroid dysfunction-related oxidative stress. A low thyroid hormone level may disrupt existing adipokines in circulation, such as tumor necrosis alpha, adiponectin, and leptin, causing subsequent hepatic inflammation and liver fibrosis [16, 31, 32]. Additionally, autoimmune-related hypothyroidism is also hypothesized to mediate the association between hypothyroidism and liver fibrosis. Several investigations have revealed that patients with Hashimoto’s thyroiditis were more likely to have fibrosis compared to euthyroid [33, 34].

Our meta-analysis presented a significant association between hypothyroidism and liver fibrosis risk despite variation of diagnostic methods. A novel cut-off of TSH ≥ 2.5, also known as low-normal thyroid function, has been rigorously studied previously, as it better reflects various health problems compared to the traditional cut-off, such as insulin resistance, prediabetes, dyslipidemia, atherosclerotic disease, chronic kidney disease, worse outcome in heart failure patients, and other common cardiometabolic disorders in several population studies [12, 35-37]. However, to date, only three studies have investigated the association between low-normal thyroid function and NAFLD, as well as liver fibrosis risk [9, 10, 38].

Strengths and limitations

This is an updated meta-analysis of the association between hypothyroidism and the risk of liver fibrosis in NAFLD patients. Although having a similar result to a prior meta-analysis [39], our study also presents summarized novel evidence regarding the cut-off of thyroid function which better reflects cardiometabolic disorders. Low-normal thyroid function is reported to be associated with a modest increase of plasma total cholesterol, LDL cholesterol and triglycerides, thus conveying a pro-atherogenic process which contributes to advanced oxidative stress, which is a huge contributor to liver fibrosis in NAFLD patients. Thus, screening, which then leads to the early treatment of subclinical hypothyroidism, might be of clinical benefit in reducing the risk of liver fibrosis in NAFLD patients [11, 12].

However, our meta-analysis has some limitations. First, the number of powered studies was limited. Second, the methods of NAFLD and fibrosis diagnosis varied and could have contributed to the bias. Significant liver fibrosis in included studies was assessed variously through different methods, through liver stiffness measurement using transient elastography with a cut-off of ≥ 8 kPa and liver biopsy according to Brunt and Kleiner criteria. Advanced liver fibrosis was also estimated by a surrogate marker (FIB-4 index) in 1 study and liver biopsy in another one. Third, because the nature of the studies were all observational, potential cause and effect relationships could not be determined for certain. These data still need to be confirmed with further prospective interventional studies, incorporating thyroid hormone replacement.

Conclusions

Hypothyroidism is associated with an increased risk of significant liver fibrosis and advanced fibrosis in NAFLD patients.

Disclosure

The authors declare no conflict of interest.

References

1 

Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999-2014.e1.

2 

Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.

3 

Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-2273.

4 

Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-97.e10.

5 

Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-1554.

6 

Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612.

7 

Chi HC, Tsai CY, Tsai MM, et al. Molecular functions and clinical impact of thyroid hormone-triggered autophagy in liverrelated diseases. J Biomed Sci 2019; 26: 24.

8 

Guo Z, Li M, Han B, Qi X. Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis. Dig Liver Dis 2018; 50: 1153-1162.

9 

Kim D, Kim W, Joo SK, et al. Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin Gastroenterol Hepatol 2018; 16: 123-131.e1.

10 

Martínez-Escudé A, Pera G, Costa-Garrido A, et al. TSH levels as an independent risk factor for NAFLD and liver fibrosis in the general population. J Clin Med 2021; 10: 2907.

11 

Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: A review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab 2013; 98: 3562-3571.

12 

van Tienhoven-Wind LJ, Dullaart RP. Low-normal thyroid function and the pathogenesis of common cardio-metabolic disorders. Eur J Clin Invest 2015; 45: 494-503.

13 

Sinha RA, You SH, Zhou J, et al. Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy. J Clin Invest 2012; 122: 2428-2438.

14 

Arner P, Bolinder J, Wennlund A, Ostman J. Influence of thyroid hormone level on insulin action in human adipose tissue. Diabetes 1984; 33: 369-375.

15 

Fuchs CD, Claudel T, Trauner M. Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends Endocrinol Metab 2014; 25: 576-585.

16 

Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761.

17 

Cable EE, Finn PD, Stebbins JW, et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. Hepatology 2009; 49: 407-417.

18 

Perra A, Simbula G, Simbula M, et al. Thyroid hormone (T3) and TRbeta agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. FASEB J 2008; 22: 2981-2989.

19 

Liu L, Yu Y, Zhao M, et al. Benefits of levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients. Int J Endocrinol 2017; 2017: 5753039.

20 

Nanthakumar CB, Hatley RJ, Lemma S, et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat Rev Drug Discov 2015; 14: 693-720.

21 

Baskol G, Atmaca H, Tanriverdi F, et al. Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes 2007; 115: 522-526.

22 

Gionfra F, De Vito P, Pallottini V, et al. The role of thyroid hormones in hepatocyte proliferation and liver cancer. Front Endocrinol 2019; 10: 532.

23 

Manka PP, Coombes JD, Bechmann LP, et al. Thyroid hormone receptor regulates hepatic stellate cell activation. J Hepatol 2017; 66: S582.

24 

Öztürk Ü, Vural P, Özderya A, et al. Oxidative stress parameters in serum and low density lipoproteins of Hashimoto’s thyroiditis patients with subclinical and overt hypothyroidism. Int Immunopharmacol 2012; 14: 349-352.

25 

Chen WJ, Lin KH, Lee YS. Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha1(I) collagen gene expression by thyroid hormone receptor. Mol Cell Endocrinol 2000; 162: 45-55.

26 

Drobnik J, Ciosek J, Slotwinska D, et al. Experimental hypothyroidism increases content of collagen and glycosaminoglycans in the heart. J Physiol Pharmacol 2009; 60: 57-62.

27 

Klein LE, Sigel AV, Douglas JA, Eghbali-Webb M. Upregulation of collagen type I gene expression in the ventricular myocardium of thyroidectomized male and female rats. J Mol Cell Cardiol 1996; 28: 33-42.

28 

Ghose Roy S, Mishra S, Ghosh G, Bandyopadhyay A. Thyroid hormone induces myocardial matrix degradation by activating matrix metalloproteinase-1. Matrix Biol 2007; 26: 269-279.

29 

Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem 2014; 57: 3912-3923.

30 

Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis 2013; 230: 373-380.

31 

Musso G, Gambino R, Durazzo M, et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-1183.

32 

Yu H, Yang Y, Zhang M, et al. Thyroid status influence on adiponectin, acylation stimulating protein (ASP) and complement C3 in hyperthyroid and hypothyroid subjects. Nutr Metab (Lond) 2006; 3: 13.

33 

Liu M, Liu W, Zhang P, et al. Left ventricular myocardial T1 mapping and strain analysis evaluate cardiac abnormality in hypothyroidism. Int J Cardiovasc Imaging 2019; 35: 507-515.

34 

Yao Z, Gao X, Liu M, et al. Diffuse myocardial injuries are present in subclinical hypothyroidism: a clinical study using myocardial T1-mapping quantification. Sci Rep 2018; 8: 4999.

35 

Chen YY, Shu XR, Su ZZ, et al. A low-normal free triiodothyronine level is associated with adverse prognosis in euthyroid patients with heart failure receiving cardiac resynchronization therapy. Int Heart J 2017; 58: 908-914.

36 

Dullaart RP, van den Berg EH, van der Klauw MM, Blokzijl H. Low normal thyroid function attenuates serum alanine aminotransferase elevations in the context of metabolic syndrome and insulin resistance in white people. Clin Biochem 2014; 47: 1028-1032.

37 

Kim SW, Jeon JH, Moon JS, et al. Low-normal free thyroxine levels in euthyroid male are associated with prediabetes. Diabetes Metab J 2019; 43: 718-726.

38 

Manka P, Bechmann L, Best J, et al. Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis. Dig Dis Sci 2019; 64: 2351-2358.

39 

Bano A, Chaker L, Muka T, et al. Thyroid function and the risk of fibrosis of the liver, heart, and lung in humans: a systematic review and meta-analysis. Thyroid 2020; 30: 806-820.

Copyright: © 2022 Clinical and Experimental Hepatology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.